DESIRIAL® is the first antioxidant hyaluronic acid based gel specifically formulated to preserve women’s intimate health.
Entirely dedicated to women’s intimate health, DESIRIAL® viscosupplement solution developed by Laboratoires VIVACY opens new treatment options in Gynecology and Intimate Plastic Surgery.
As many as 80% of women entering menopause are affected by vaginal dryness and about 50% of women completing menopause continue to experience vaginal dryness.
Vaginal and/or vulvar dryness may affect women at any period of their lives, whether it is iatrogenic in origin (e.g. isotretinoin, tricyclic antidepressants, neuroleptics, etc.), or linked to menopause, particularly in the absence of Hormone Replacement Therapy (HRT).
During menopause, there is a decrease of estrogen secretion, which has an effect on fibroblasts, and leads to progressive hypotrophy of the dermis with flattening of the dermal-epidermal junction:
- The vaginal mucosa becomes dry (the connective tissue has less vascularisation, is less hydrated and becomes thinner) just like the whole skin. The glandular cells getting less nutrition become atrophic and begin to function poorly.
- The skin loses its elasticity. The collagen and elastin fibres degenerate and decrease, the fibroblasts become hypoactive and the Type III collagen increases to the detriment of the Type I collagen.
As a result, skin dryness, loss of elasticity, flaccidity and fragility appear. Estrogen levels drop (related to menopause) leads to labia majora hypotrophy, characterized also by vulvar dryness.
Injection of cross-linked hyaluronic acid DESIRIAL® into the dermis of the labium can help rehydrate, biostimulate and restore fibroblast activity to maintain proper functioning of the female genital tissues.
for peri-menopausal, menopausal women and women in reproductive age with a predisposition for or manifest signs of moderate to severe hypotrophy or atrophy of the vulva labia majora ? Reshaping of the labia majora of the vulva in case of moderate to severe hypotrophy.
IPN-like cross-linked NaHa at 21mg/g
2x27G 1/2 needles + 1x80G 80 cannula